On March 11, 2025 Caris Life Sciences (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, reported that the company and collaborators within the Caris Precision Oncology Alliance (Caris POA) will collectively present five studies across multiple gynecological tumor types at the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, March 14-17, 2025, in Seattle, Washington (Press release, Caris Life Sciences, MAR 11, 2025, View Source [SID1234651083]). The findings demonstrate the power of Caris’ comprehensive clinico-genomic database to enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan and response to treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Caris and our POA collaborators are proud to present five studies at this year’s SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment for gynecological cancers," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "By utilizing our comprehensive clinico-genomic database, we have improved the understanding of tumor biology and shown how specific molecular characteristics affect prognosis and treatment efficacy. This work exemplifies our dedication to advancing precision medicine and optimizing oncology treatment strategies."
Oral Presentations
Improved Real World Outcomes in Patients with Low-Grade Serous Ovarian Carcinoma and MAPK Pathway Mutations Treated with Trametinib
Focused Forum IV Finding IMPACT: The Needle in the Haystack
March 15: 4:52-4:58 PM PST
Impact of CCNE1 Amplification on Molecular Signatures and Patient Outcomes in High Grade Serous Ovarian and Endometrial Cancer
Focused Forum X Future IMPACT
March 16: 3:32-3:40 PM PST
Oral Featured Poster
Genomic and Immunohistochemical Characterization of NSMP Endometrial Cancer: A Novel Approach to Estrogen Receptor Positivity
Oral Featured Poster Session II: Multiple Ways to Make an IMPACT
March 15: 4:23-4:26 PM PST
Posters
GPR171, a Prognostic Marker of Improved Survival in Cervix Cancer – A Deep South Consortium in Oncology (DSCO) Project
Poster Session | March 16, 2:00 – 3:30 PM PST
Comparison of Breast and Gastric HER2 Immunohistochemistry (IHC) Scoring Criteria in the Assessment of Endometrial Carcinoma
Poster Session | March 16, 2:00 – 3:30 PM PST
Poster and abstract summaries highlighting this research will be available onsite at Caris’ booth #416. The full abstracts will be available on the Caris website following the presentation.
The Caris POA includes 96 cancer centers, academic institutions, research consortia and healthcare systems, including 47 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.